Cell-free DNA in large B-cell lymphoma: MRD and beyond
Seminars in Hematology, ISSN: 0037-1963, Vol: 60, Issue: 3, Page: 142-149
2023
- 14Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures14
- Readers14
- 14
- Mentions1
- News Mentions1
- News1
Most Recent News
Investigators at Stanford University Detail Findings in B-Cell Lymphoma (Cell-free Dna In Large B-cell Lymphoma: Mrd and Beyond)
2024 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- Researchers detail new data in Oncology - B-Cell Lymphoma.
Article Description
Large B-cell lymphomas (LBCLs) are a strikingly diverse set of diseases, including clinical, biological, and molecular heterogeneity. Despite a wealth of information resolving this heterogeneity in the research setting, applying molecular features routinely in the clinic remains challenging. The advent of circulating tumor DNA (ctDNA) liquid biopsies promises to unlock additional molecular information in the clinic, including mutational genotyping, molecular classification, and minimal residual disease detection. Here, we examine the technologies, applications, and studies exploring the utility of ctDNA in LBCLs.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0037196323000525; http://dx.doi.org/10.1053/j.seminhematol.2023.06.004; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85165336512&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37474409; https://linkinghub.elsevier.com/retrieve/pii/S0037196323000525; https://dx.doi.org/10.1053/j.seminhematol.2023.06.004
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know